Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Gains from Investment Securities: 2012-2025

Historic Gains from Investment Securities for Fennec Pharmaceuticals (FENC) over the last 6 years, with Sep 2025 value amounting to $50,000.

  • Fennec Pharmaceuticals' Gains from Investment Securities rose 1566.67% to $50,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $170,000, marking a year-over-year increase of 15.65%. This contributed to the annual value of $176,000 for FY2024, which is 125.64% up from last year.
  • Fennec Pharmaceuticals' Gains from Investment Securities amounted to $50,000 in Q3 2025, which was down 49.49% from $99,000 recorded in Q2 2025.
  • Fennec Pharmaceuticals' Gains from Investment Securities' 5-year high stood at $5.0 million during Q1 2023, with a 5-year trough of $3,000 in Q3 2024.
  • For the 3-year period, Fennec Pharmaceuticals' Gains from Investment Securities averaged around $536,200, with its median value being $27,000 (2023).
  • In the last 5 years, Fennec Pharmaceuticals' Gains from Investment Securities crashed by 99.71% in 2023 and then soared by 1,566.67% in 2025.
  • Quarterly analysis of 5 years shows Fennec Pharmaceuticals' Gains from Investment Securities stood at $3.7 million in 2021, then increased by 22.26% to $28,000 in 2022, then climbed by 25.00% to $35,000 in 2023, then tumbled by 74.29% to $9,000 in 2024, then surged by 1,566.67% to $50,000 in 2025.
  • Its Gains from Investment Securities stands at $50,000 for Q3 2025, versus $99,000 for Q2 2025 and $12,000 for Q1 2025.